169 results
Page 3 of 9
6-K
mn8q4h6
11 Feb 21
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
3:17pm
6-K
EX-99.2
xv9k51u6fv
11 Feb 21
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
3:17pm
6-K
EX-99.1
95xmpbnp4q9 x1i5f
16 Oct 20
Current report (foreign)
5:06pm
6-K
EX-99.1
1u3kc6khxexw
28 Sep 20
Sanofi completes Principia Biopharma Inc. acquisition
8:54am
SC TO-T
EX-99
0rr58alofmwylw wbbx
28 Aug 20
Third party tender offer statement
6:24am
SC TO-C
EX-99.5
szjz5zrc
18 Aug 20
Information about tender offer
12:00am
SC TO-C
EX-99.3
8p5oxxcuv whs
18 Aug 20
Information about tender offer
12:00am
6-K
EX-99.2
xjsrnz6
29 Jul 20
2020 Half-year Financial Report
10:13am
6-K
EX-99.2
xw9az 4m3
24 Jun 20
R&D strategy driving pipeline momentum, productivity and innovation
3:08pm
6-K
EX-99.1
okkj2
24 Jun 20
R&D strategy driving pipeline momentum, productivity and innovation
3:08pm
6-K
EX-99.2
7q46jozo1od83k
17 Jun 20
Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease
2:33pm
6-K
EX-99.4
y9kk3hjp4t4a2
3 Jun 20
Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline
11:27am
6-K
EX-99.3
v3ftym 9a1x22ev0p
30 Mar 20
Current report (foreign)
10:29am
6-K
EX-99.1
oye9jy ygjvxwfy
6 Feb 20
Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
2:20pm
SC TO-T
EX-99
vxisu292603oqqxp
27 Dec 19
Third party tender offer statement
5:27pm
6-K
EX-99.1
xf7gewufjdd4v2sl
10 Dec 19
Sanofi CEO unveils new strategy to drive innovation and growth
11:13am
6-K
EX-99.2
9rs5drn
29 Jul 19
Half-year Financial Report
10:41am
6-K
EX-99.1
rltc566nv850w
7 Jun 19
Current report (foreign)
6:39am